SECTOR
Shilpa Medicare’s arm enters into strategic partnership with Orion Corporation
May-23-2025

Shilpa Medicare’s 100% subsidiary -- Shilpa Biocare has entered into a strategic partnership with Orion Corporation (Orion), a globally recognized pharmaceutical company headquartered in Finland, out-licensing its flagship product -- Recombinant Human Albumin -- for commercialisation across the European market. The product is currently under development.

Under this agreement, Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa’s Recombinant Human Albumin in Europe. Shilpa is entitled to receive from Orion certain development and regulatory milestone payments. Shilpa has been investing in the development of this novel product for about 8 years and has also set-up a large scale fermentation facility for manufacture of recombinant human albumin to address market demand for this life saving drug at a global scale. This collaboration marks a major milestone in Shilpa’s expansion into global biosimilar and biopharmaceutical markets, leveraging Orion’s strong regional presence, regulatory expertise, and well-established commercial infrastructure.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.


  RELATED NEWS >>